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On the cutting edge of clinical pulmonary medicine
in COPDThis supplement describes the proceedings from a
meeting convened in Trevi, Italy, to discuss the
cutting edge of clinical pulmonary medicine in
chronic obstructive pulmonary disease (COPD). This
meeting focused on the management of stable
COPD. Clinical approaches to the prevention and
treatment of exacerbations is a very important
topic, which we would like to address at a
subsequent meeting.
COPD represents a serious and growing threat to
public health. It is projected that by 2010, deaths
arising from COPD will be more common in
European countries than from pneumonia, some
forms of cancer (colorectal, stomach and breast),
cirrhosis of the liver and road traffic accidents. In
fact, it is predicted that by 2020, COPD will have
become the third most common cause of death
worldwide, and the fourth most important disabling
condition.
The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) was established to raise
awareness of COPD and stimulate research into
this area, as well as to develop evidence-based
guidelines for the diagnosis, treatment and man-
agement of COPD. The most recent guidelines
produced by GOLD were published in 2004 and they
define COPD as follows: ‘COPD is a disease state
characterised by airflow limitation that is not fully
reversible. The airflow limitation is usually pro-
gressive and is associated with an abnormal
inflammatory response of the lungs to noxious
particles or gases’. The American Thoracic Socie-
ty–European Respiratory Society Statement on
COPD, presented in 2004 and updated on-line,
represents the largest scientifically supported
source of information on this disease and presents
the concept that COPD has systemic consequences.
COPD represents an inflammatory response to the
inhalation of atmospheric pollution, most com-ee front matter & 2005 Elsevier Ltd. All rights reserv
med.2005.09.009monly cigarette smoke, although a number of
poorly defined genetic risk factors also play a role.
The pathophysiology underlying COPD arises from
varying degrees of airway narrowing, smooth-
muscle hypertrophy and fibrosis in the bronchioles,
intraluminal secretions, and the loss of elastic
recoil pressure that is associated with emphysema.
The hyperinflation associated with COPD—which is
often increased during exercise—is an important
factor associated with dyspnoea. In addition to this
symptom, protease–anti-protease imbalance and
increased oxidative stress probably contribute to
the development of COPD.
Patients with COPD suffer exacerbations—an
acute worsening of their condition that requires
increased medication—and this is often a result of
viral or bacterial infections. Clearly complex in
nature, COPD exerts profound systemic effects,
including elevated levels of inflammatory markers,
muscular metabolic abnormalities, and in some
cases, cachexia. As a consequence of the respira-
tory and systemic derangements, patients experi-
ence dyspnoea, fatigue, exercise intolerance,
muscular weakness, limitation of daily activities,
reduced quality of life (QoL) and, ultimately,
increased mortality.
A number of treatments are available for COPD,
including bronchodilators (short-acting and long-
acting b2-agonists and anti-cholinergics), inhaled
corticosteroids, combinations involving inhaled
corticosteroids and long-acting b2-agonists, oxygen
therapy and lung-volume-reduction surgery.
Bronchodilators reduce the airflow limitation and
hyperinflation associated with COPD, helping to
alleviate the dyspnoea associated with this disease.
To date, however, only smoking cessation has been
convincingly demonstrated to modify the progres-
sion of this disease, and only oxygen therapy has
been shown to favourably affect survival. Thised.
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data from two, very large, randomised, long-term
trials—TORCH and UPLIFT—become available.
TORCH (TOwards a Revolution in COPD Health) will
examine the long-term effects (including survival)
of the inhaled steroid, fluticasone propionate, and
the long-acting b2-agonist bronchodilator, salme-
terol, alone or in combination. UPLIFT (Under-
standing Potential Long-term Impacts on Function
with Tiotropium) will assess the effect of the long-
acting anticholinergic bronchodilator, tiotropium,
on the long-term decline in forced expiratory
volume in 1 s (FEV1) that occurs in COPD. While
these two trials are investigating the long-term
efficacy of currently available agents, a number of
new pharmacotherapeutic agents are in develop-
ment for the treatment of this disease. Many of
these agents target elements of the inflammatory
pathways because systemic inflammation is seen as
key to the pathophysiology of COPD. Such agents
include inhibitors of phosphodiesterase-4 and leu-
kotriene B4.
Pulmonary rehabilitation complements pharma-
cotherapy and is now considered central to the
management of symptomatic COPD. This form of
management has negligible effects on pulmonary
function, yet commonly provides substantial relief
from dyspnoea, increased exercise tolerance and
improved health-related QoL. Pulmonary rehabili-
tation appears to work via several mechanisms,
including reducing some of the comorbidity asso-
ciated with chronic respiratory disease (such as the
physical deconditioning associated with sedentar-
ism) and providing patients with self-management
strategies (through disease-related education).
Rehabilitation would also seem to reduce subse-
quent health care utilisation, with the valuable
cost reductions that this would imply.
The logical concept of optimising the pharmaco-
logic management of COPD patients prior to, and
during pulmonary rehabilitation to achieve greater
benefit, is becoming more widely recognised. De-
spite a growing body of research evidence, further
work is needed to determine which patients will
benefit most from pulmonary rehabilitation, how this
form of management is best prescribed, and how to
identify the most suitable practice setting, which is
dependent on the stage/phase of this disease.
Improved diagnostic and assessment methods
are also important in our management of COPD.Spirometry, and the measurement of the forced
vital capacity (FVC) and FEV1, are still our mainstay
in establishing a diagnosis of this disease. Never-
theless, other measurements, including the level of
dyspnoea, the degree of COPD-associated weight
loss, and impairments in functional status and
health status, also provide important information
for assessing morbidity and predicting morta-
lity. For instance, the recently developed BODE
index, which incorporates body-mass index (B),
airflow obstruction (O), dyspnoea (D) and exercise
capacity (E) into one score, is a better predictor
of survival in COPD than any of its individual
components.
Extensive research into the genetic basis of COPD
is also ongoing. Findings from such investigations
may assist with the identification of patients at risk
for developing COPD. Novel methods of character-
ising the anatomical and mechanistic changes
associated with COPD may also provide greater
phenotypic discrimination and therefore, may be
useful in more precisely directing therapy. Less
reliance would accordingly be placed upon spiro-
metry as the main means of assessing response to
therapy.
Such exciting developments deepen our under-
standing and widen the scope for managing COPD.
Improved diagnosis and evaluation, coupled with
better treatment and management regimens for
COPD, should improve the efficiency of our treat-
ment, enhancing symptomatic relief, increasing
patient participation in daily activities, and per-
haps, favourably modifying the course of this
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